the World Congress of Gastroenterology at ACG2017!
Industry-Sponsored Satellite Symposia
Open to all WCOG at ACG2017 attendees, industry-sponsored satellite symposia provide additional educational opportunities for attendees. These programs are independent of the World Congress of Gastroenterology at ACG2017 Meeting and ACG is not the continuing medical education provider for these programs.
From Induction to Remission in Moderate to Severe Ulcerative Colitis: Pursuing Unmet Needs through Therapies with Novel Mechanisms of Action
Saturday, October 14, 2017 | 5:30 pm – 7:30 pm | Hyatt Regency Orlando, Plaza G
Activity Chair: William J. Sandborn, MD
Ulcerative colitis (UC) has gained importance over the past few decades due to its increasing incidence rate worldwide. Strategies currently used by physicians in the treatment of moderate to severe UC are frequently inadequate to avoid disease flares, prevent structural damage and disability, and restore quality of life. This CME activity will assess the role of emerging therapies with novel mechanisms of action, the potential impact of emerging pharmacological therapies on patient-reported outcomes, as well as the latest evidence pertaining to the safety and efficacy of therapies with unique mechanisms of action in patients with moderate to severe UC.
Supported by an Educational Grant from Pfizer, Register Here.
Trial by Jury: Examining the Current Guidelines for Diagnosis and Management of IBS and CIC
Saturday, October 14, 2017 | 5:30 pm – 7:30 pm | Hyatt Regency Orlando, Plaza HIJK
Factuly: Brooks D. Cash, MD, FACG, William D. Chey, MD, FACG, Anthony J. Lembo, MD, FACG, Baha Moshiree, MD, MSCI Mark Pimentel, MD, FACG
We will follow a Trial by Jury approach reviewing contemporary issues relevant to diagnosis and managing irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC). As a participant juror in these mock trials, you will have the opportunity to hear both sides of each controversy and cast your vote at the end of each debate.
Supported by educational grants from Commonwealth Diagnostics International, Inc., Salix Pharmaceuticals and Synergy Pharmaceuticals, Register Here.
Solving the PBC Mystery: From Missing Clues to Diagnosis and Improved Treatment
Saturday, October 14, 2017 | 7:30 pm – 9:30 pm | Hyatt Regency Orlando, Plaza DEF
Primary biliary cholangitis (PBC) has considerable impact on morbidity, mortality, and health-related quality of life, yet the diagnosis is often delayed. Advances in the understanding of the pathophysiology and diagnosis of PBC and new and emerging treatments have the potential to improve patient outcomes as these advances are integrated into clinical practice. Our panelists will discuss new and emerging treatments and more during this live symposia.
Supported by an independent educational grant from Intercept Pharmaceuticals, Register Here.
Virtual Journey Through IBS-D: Seeing Is Believing
Saturday, October 14, 2017 | 7:30 pm – 9:30 pm | Hyatt Regency Orlando, Regency V
Faculty: Brennan M. R. Spiegel, MD, MSHS, FACG, Lin Chang, MD, FACG, Darren M. Brenner, MD
Irritable bowel syndrome D (IBS-D) is complex and multifactorial in nature. Our expert panel will explore the etiology and pathophysiology of IBS-D, diagnosis and clinical decision points, and the mechanism of current therapies. This live symposium will feature mixed reality segments to illustrate key clinical points in the journey through IBS-D.
Provided by AGA Institute, Inc. and Medscape Education, supported by Allergan and Salix Pharmaceuticals, Register Here.
A Family Feud in IBS-C and CIC: Who are the Experts?
Sunday, October 15, 2017 | 5:30 am – 7:30 am | Hyatt Regency Orlando, Regency V
Host: Alok Patel, MD
Faculty: Brooks D. Cash, MD, FACG, William D. Chey, MD, FACG
Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are among the most common bowel disorders seen by gastroenterologists. In this live, interactive program, audience participants will test their knowledge about IBS-C and CIC in a "Family Feud"-style game show moderated by a professional host. Following the game show, 2 faculty experts will go in-depth into the pathogenesis, symptomatology, diagnosis, and treatment selection for IBS-C and CIC, and share insights about effective provider-patient communication to improve patient outcomes.
Provided by Medscape Education, supported by Allergan and Ironwood Pharmaceuticals, Register Here.
Improving Colorectal Cancer Prevention: The Latest Advances to Improve Adenoma Detection Rates
Sunday, October 15, 2017 | 7:30 pm – 9:30 pm | Hyatt Regency Orlando, Plaza G
Activity Chair: Douglas K. Rex, MD
Colorectal cancer (CRC) is the third most common type of cancer worldwide and second deadliest form of cancer in the United States. Current estimates suggest that up to 25% of adenomas are missed with current colonoscopy technologies, primarily due to poor visualization in folds and other difficult-to-detect areas. Technological advances in recent years have improved detection rates. This CME activity will review appropriate screening and prevention efforts for the early detection of patients with CRC, as well as evaluate the clinical safety and efficacy of new and emerging technologies for the detection of lesions in patients undergoing colonoscopy for CRC screening.
Supported by an Educational Grant from Aries Pharmaceuticals, Register Here.
Diagnosis and Treatment of NASH: Evidence-Based Discussion of an Urgent Clinical Need
Monday, October 16, 2017 | 5:30 am – 7:30 am | Orange County Convention Center - 304A-D and Corridor
Supported by an educational grant from Allergan, Inc.
Translating Advances in the Identification and Treatment of Recurrent C. difficile Infection into Clinical Practice and Improved Outcomes
Monday, October 16, 2017 | 7:00 pm – 9:00 pm | Hyatt Regency Orlando, Plaza G
Faculty: David Binion, MD, Paul Feuerstadt, MD, FACG, Sahil Khanna, MBBS
An interactive discussion on the importance of appropriately identifying and treating C. difficile (CDI) and recurrent CDI. CDI is associated with significant morbidity and mortality. Further, recurrence of CDI is common after an initial episode. Although a number of therapies with varying mechanisms of action are available to treat CDI and prevent recurrence, the management of recurrent CDI is complex and challenging. Clinicians require up-to-date knowledge of evidence-based treatment of recurrent CDI to reduce its burden and improve clinical outcomes.
Supported by an educational grant from Merck & Company, Register Here.
Inside Tract: Exploring the Science of GC-C Agonists in Constipation
Monday, October 16, 2017 | 7:00 pm – 9:00 pm | Hyatt Regency Orlando, Regency R
Faculty: Brooks D. Cash, MD, FACG (Chair), Darren M. Brenner, MD, Scott A. Waldman, MD, PhD
This program will include presentations that examine the science of guanylate cyclase-C (GC-C) agonists, their differences, and their role in bowel function. Program participants will view data from a recent study of patient and physician perspectives on chronic idiopathic constipation (CIC) and current treatments.
This program is supported by Synergy Pharmaceuticals Inc.